Johnson & Johnson (JNJ) Complaint Causes Court To Order Ocular Insight to Discontinue Certain Advertising/Promotional Claims
More News related to JNJ
- Cougar Biotechnology Announces Successful Completion of Johnson & Johnson's Initial Tender Offer and Commencement of Subsequent Offering Period
- Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
- Unusual 11 Mid-Day Movers 7/2: NAVI, AVNR, ESLR, ELN Higher; DSCO, SEPR, TIVO, ILMN Lower
- Notable Mergers and Acquisitions of the Day 7/2: JNJ/ELN, FCSX/IAAC, LSTR
- Morning Movers 7/2: ELN, QUIK, ESLR Higher; DSCO, LEA, SEPR, ILMN, MANH Lower
Following a complaint filed in July 2008 by Johnson & Johnson Vision Care (NYSE: JNJ), a United States district court in New York has ordered, on both parties' consent, Ocular Insight, Inc. to permanently discontinue stating or communicating in its advertising or promotional materials or activities to eye care professionals for the company's Clear 58(R) contact lenses in the United States.
"Doctors write prescriptions for the particular contact lens brand that best fits the overall comfort, eye health, and vision needs of the patient," she adds. "Contact lenses are medical devices that require a prescription, and contact lens wearers should never substitute a different brand than they presently have without the approval of their eye doctor."
Related Categories
Corporate NewsFDA
Stocks Mentioned
-1.09Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
